You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline Snapshot as of August 1, 2017

  • Discovery Projects
  • Phase 1
    13
  • Phase 2
    5
  • Phase 3
    20
  • Registration
    4
  • Total42
 
Compound Name
Indication
Phase
Submission Type
Compound Typesort descending
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
PF-04518600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
OX40 receptor Agonist
Go to clinical trial
Cancer, Combo w/ avelumab (PD-L1) (Biologic) Phase 1 New Molecular Entity Biologic
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CD137 Agonist
Go to clinical trial
Cancer (Biologic), Combo w/ Merck's Keytruda (PD-1, pembrolizumab), Combo w/ Kyowa Hakko Kirin's anti-CCR4 antibody (mogamulizumab) Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06647263
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
ephrin-A4 (EFNA4) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06747143
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
chemokine (C-X-C motif) receptor 4 (CXCR4) Inhibitor
Go to clinical trial
Acute Myeloid Leukemia (Biologic) Phase 1 New Molecular Entity Biologic
  •